Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31097912 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL2904552 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL32681153 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL7684 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL637241 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL11542843 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Water SCHEMBL18124365 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Water SCHEMBL19283519 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11444696 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11444694 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| EP-4460503-A1 | IMPROVED PROCESS FOR THE PREPARATION OF UPADACITINIB | MSN Laboratories Private Limited, R&D Center (IN) | 2024-11-13 | — | — | EP | claimed |
| WO-2024130425-A1 | METHODS OF MAKING 2-AMINO-L-(3-HYDROXY-2,6-DIMETHYLPHENYL)-5,6- DIMETHYL-LH-PYRROLO-[2,3-B]PYRIDINE-3-CARBOXAMIDE, A MYTL INHIBITOR | REPARE THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | claimed |
| EP-3927689-B1 | PROCESSES FOR PREPARING (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE OR A SALT THEREOF AND PROCESSES FOR PREPARING TOFACITINIB USING THE SAME | YUHAN CORP (KR) | 2024-01-24 | — | — | EP | claimed |
| US-20230416224-A1 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | ZEVRA DENMARK AS (DK) | 2023-12-28 | — | — | US | claimed |
| EP-4247792-A1 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | Zevra Denmark A/S (DK) | 2023-09-27 | — | — | EP | claimed |
| CN-116783164-A | Process for preparing apremilast citrate and intermediates thereof | 泽维拉丹麦股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| WO-2023131978-A1 | IMPROVED PROCESS FOR THE PREPARATION OF UPADACITINIB | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-07-13 | — | — | WO | claimed |
| US-8399655-B2 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | SHIRE CANADA INC. (CA) | 2013-03-19 | — | — | US | claimed |
| WO-2012137047-A1 | A PROCESS FOR PREPARING FESOTERODINE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2012-10-11 | — | — | WO | claimed |
| WO-2012022994-A1 | PREPARATION PROCESS OF VILDAGLIPTIN | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2012-02-23 | — | — | WO | claimed |
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2012-01-26 | — | — | US | claimed |
| WO-2012010316-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2012-01-26 | — | — | WO | claimed |
| US-20110257397-A1 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | CIMPOIA ALEX | 2011-10-20 | — | — | US | claimed |
| US-20100331544-A1 | METHOD FOR PRODUCING (1R,5S) ANHYDROECGONINE ESTER SALTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-30 | — | — | US | claimed |
| EP-1866303-A1 | PROCESS AND METHODS FOR THE PREPARATION OF OPTICALLY ACTIVE CIS-2-HYDROXYMETHYL-4-(CYTOSIN-1´-YL)-1,3-OXATHIOLANE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Shire BioChem Inc. (CA) | 2007-12-19 | — | — | EP | claimed |
| WO-2006096954-A1 | PROCESS AND METHODS FOR THE PREPARATION OF OPTICALLY ACTIVE CIS-2-HYDROXYMETHYL-4-(CYTOSIN-1´-YL)-1,3-OXATHIOLANE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SHIRE BIOCHEM INC. (CA) | 2006-09-21 | — | — | WO | claimed |
| US-20060199786-A1 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl) -1,3-oxathiolane or pharmaceutically acceptable salts thereof | SHIRE CANADA INC. (CA) | 2006-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | FDPS, PCTP, MTTP | CES1 751/4885SRC 52/4885CES2 3211/4885 |
| US-20100331544-A1 | METHOD FOR PRODUCING (1R,5S) ANHYDROECGONINE ESTER SALTS | GNE, ABHD5, GALE | CES1 241/4885SRC 3552/4885CES2 523/4885 |
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | RCC2, EP300, SIGMAR1 | CES1 1309/4885SRC 131/4885CES2 475/4885 |
| US-20230416224-A1 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | ACLY, AURKC, AURKA | CES1 1449/4885SRC 583/4885CES2 3216/4885 |
| US-20110257397-A1 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | SPECC1L, MTHFD1, HCCS | CES1 50/4885SRC 3200/4885CES2 366/4885 |
| US-20060199786-A1 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl) -1,3-oxathiolane or pharmaceutically acceptable salts thereof | SPECC1L, MTHFD1, HCCS | CES1 50/4885SRC 3200/4885CES2 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.